Yes, I now think those who were, like me, anticipating a near term $50 T/O, are going to be sadly disappointed, valuations or no valuations.
Figures of that level and above, should they eventuate, are likely another 3 to 4 years off. Like it or not, an SP of $15 after 3 successful 2591 P2 trials was not on my radar. (Hands up anyone who would have predicted that.)
Quite disappointing really.
The Whens and Whys of Top Biotech M&A Deals, page-14
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.25 |
Change
-0.100(0.81%) |
Mkt cap ! $1.565B | |||
| Open | High | Low | Value | Volume |
| $12.20 | $12.25 | $12.02 | $3.677M | 302.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1579 | $12.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.26 | 1199 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |